Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NYMX

Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis

About Nymox Pharmaceutical Stock (NASDAQ:NYMX)

Key Stats

Today's Range
N/A
50-Day Range
$0.19
$0.47
52-Week Range
N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

Nymox Announces Filing of Annual Report
Nymox Annual Report
Notice: Major payout due November 19th - are you on the list?
On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...
Nymox December 27 Message to Shareholders
See More Headlines

NYMX Stock Analysis - Frequently Asked Questions

Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/14/2014
Today
10/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-6,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
41,637,000
Market Cap
$18.10 million
Optionable
Optionable
Beta
0.64
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:NYMX) was last updated on 10/5/2024 by MarketBeat.com Staff
From Our Partners